Key result
Calcium channel blockers and angiotensin II antagonists appear to be the best initial antihypertensive choices for patients with coexisting COPD.
Why the study?
What are the optimal antihypertensive drug therapies for patients with systemic hypertension and coexisting chronic obstructive pulmonary disease?
What are the optimal antihypertensive drug therapies for patients with systemic hypertension and coexisting chronic obstructive pulmonary disease?
Calcium channel blockers and angiotensin II receptor blockers are recommended as the best initial antihypertensive choices for patients with coexisting COPD, based on available literature.
Supports consideration of calcium channel blockers or ARBs in hypertensive COPD; leaves open confirmation by randomized trials.
Systemic hypertension and chronic obstructive pulmonary disease (COPD) frequently coexist in the same patient, especially in the elderly. Today, a wide variety of antihypertensive drugs with different mechanisms of action are available to the prescribing physician. In addition, combination drugs for hypertension are becoming increasingly popular. Certain antihypertensive drugs can affect pulmonary function. Therefore the management of such patients can present therapeutic challenges. We have examined the literature pertaining to the use of antihypertensive drugs in patients with systemic hypertension and coexisting COPD. Although data are often limited or of poor quality, we have attempted to review and then provide recommendations regarding the use of all the specific classes of antihypertensive drug therapies including combination drugs in patients with COPD. The antihypertensive agents reviewed include diuretics, aldosterone receptor blockers, beta blockers, combined alpha and beta blockers, angiotensin-converting enzyme inhibitors, angiotensin II antagonists, calcium channel blockers, alpha-1 blockers, centrally acting drugs, direct vasodilators, and combinations of these drugs. Of these classes, calcium channel blockers and angiotensin II antagonists appear to be the best initial choices if hypertension is the only indication for treatment. However, the limited data available on many of these drugs suggest that additional studies are needed to more precisely determine the best treatment choices in this widely prevalent patient group.
No takes yet. Share an insight, caveat, or question.
Banach et al. (2013) conducted a review in Systemic hypertension and chronic obstructive pulmonary disease (COPD). Antihypertensive drugs was evaluated. Calcium channel blockers and angiotensin II antagonists appear to be the best initial antihypertensive choices for patients with coexisting COPD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: